{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T20:19:57Z","timestamp":1775679597344,"version":"3.50.1"},"reference-count":14,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T00:00:00Z","timestamp":1513209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2017,12,14]],"date-time":"2017-12-14T00:00:00Z","timestamp":1513209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Blood Cancer Journal"],"DOI":"10.1038\/s41408-017-0015-x","type":"journal-article","created":{"date-parts":[[2017,12,8]],"date-time":"2017-12-08T16:52:49Z","timestamp":1512751969000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Correlation between markers of bone metabolism and vitamin D levels in patients with monoclonal gammopathy of undetermined significance (MGUS)"],"prefix":"10.1038","volume":"7","author":[{"given":"Brea","family":"Lipe","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suman","family":"Kambhampati","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter Van","family":"Veldhuizen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abdulraheem","family":"Yacoub","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Omar","family":"Aljitawi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Mikhael","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,12,14]]},"reference":[{"key":"15_CR1","doi-asserted-by":"publisher","first-page":"5412","DOI":"10.1182\/blood-2008-12-194241","volume":"113","author":"O Landgren","year":"2009","unstructured":"Landgren, O. et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: a prospective study. Blood 113, 5412\u20135417 (2009).","journal-title":"Blood"},{"key":"15_CR2","doi-asserted-by":"publisher","first-page":"5418","DOI":"10.1182\/blood-2008-12-195008","volume":"113","author":"BM Weiss","year":"2009","unstructured":"Weiss, B. M., Abadie, J., Verma, P., Howard, R. S. & Kuehl, W. M. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood 113, 5418\u20135422 (2009).","journal-title":"Blood"},{"key":"15_CR3","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1038\/leu.2010.60","volume":"24","author":"RA Kyle","year":"2010","unstructured":"Kyle, R. A. et al. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering (asymptomatic) multiple myeloma: IMWG consensus perspectives risk factors for progression and guidelines for monitoring and management. Leukemia 24, 1121\u20131127 (2010).","journal-title":"Leukemia"},{"key":"15_CR4","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1182\/blood-2005-03-1038","volume":"106","author":"SV Rajkumar","year":"2005","unstructured":"Rajkumar, S. V. et al. Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance. Blood 106, 812\u2013817 (2005).","journal-title":"Blood"},{"key":"15_CR5","doi-asserted-by":"publisher","first-page":"2582","DOI":"10.1056\/NEJMoa070389","volume":"356","author":"RA Kyle","year":"2007","unstructured":"Kyle, R. A. et al. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma. N. Engl. J. Med. 356, 2582\u20132590 (2007).","journal-title":"N. Engl. J. Med."},{"key":"15_CR6","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1002\/jcb.22403","volume":"109","author":"GD Roodman","year":"2010","unstructured":"Roodman, G. D. Pathogenesis of myeloma bone disease. J. Cell Biochem. 109, 283\u2013291 (2010).","journal-title":"J. Cell Biochem."},{"key":"15_CR7","doi-asserted-by":"publisher","first-page":"2651","DOI":"10.1182\/blood-2010-04-282848","volume":"116","author":"SY Kristinsson","year":"2010","unstructured":"Kristinsson, S. Y. et al. Monoclonal gammopathy of undetermined significance and risk of skeletal fractures: a population-based study. Blood 116, 2651\u20132655 (2010).","journal-title":"Blood"},{"key":"15_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1359\/jbmr.0301212","volume":"19","author":"LJ Melton 3rd","year":"2004","unstructured":"Melton, L. J. 3rd et al. Fracture risk in monoclonal gammopathy of undetermined significance. J. Bone Miner. Res. 19, 25\u201330 (2004).","journal-title":"J. Bone Miner. Res."},{"key":"15_CR9","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1182\/blood-2013-05-505776","volume":"123","author":"JN Farr","year":"2014","unstructured":"Farr, J. N. et al. Altered cortical microarchitecture in patients with monoclonal gammopathy of undetermined significance. Blood 123, 647\u2013649 (2014).","journal-title":"Blood"},{"key":"15_CR10","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1210\/jc.2008-1454","volume":"94","author":"D Bikle","year":"2009","unstructured":"Bikle, D. Nonclassic actions of vitamin D. J. Clin. Endocrinol. Metab. 94, 26\u201334 (2009).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"15_CR11","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1002\/ajh.21412","volume":"84","author":"AC Ng","year":"2009","unstructured":"NgA. C., KumarS. K., RajkumarS. V. & DrakeM. T. Impact of vitamin D deficiency on the clinical presentation and prognosis of patients with newly diagnosed multiple myeloma. Am. J. Hematol. 84, 397\u2013400 (2009).","journal-title":"Am. J. Hematol."},{"key":"15_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1002\/ajh.21619","volume":"85","author":"T Diamond","year":"2010","unstructured":"Diamond, T., Golombick, T. & Manoharan, A. Vitamin D status may effect the skeletal complications of multiple myeloma. Am. J. Hematol. 85, 302\u2013303 (2010).","journal-title":"Am. J. Hematol."},{"key":"15_CR13","doi-asserted-by":"publisher","first-page":"686","DOI":"10.1111\/j.1365-2141.2004.05092.x","volume":"126","author":"M Politou","year":"2004","unstructured":"Politou, M. et al. Role of receptor activator of nuclear factor-kappa B ligand (RANKL), osteoprotegerin and macrophage protein 1-alpha (MIP-1a) in monoclonal gammopathy of undetermined significance (MGUS). Br. J. Haematol. 126, 686\u2013689 (2004).","journal-title":"Br. J. Haematol."},{"key":"15_CR14","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1111\/j.1365-2141.2008.07214.x","volume":"142","author":"A Badros","year":"2008","unstructured":"Badros, A. et al. Prevalence and significance of vitamin D deficiency in multiple myeloma patients. Br. J. Haematol. 142, 492\u2013494 (2008).","journal-title":"Br. J. Haematol."}],"container-title":["Blood Cancer Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41408-017-0015-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-017-0015-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41408-017-0015-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,29]],"date-time":"2024-06-29T15:08:36Z","timestamp":1719673716000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41408-017-0015-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,12,14]]},"references-count":14,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2017,12]]}},"alternative-id":["15"],"URL":"https:\/\/doi.org\/10.1038\/s41408-017-0015-x","relation":{},"ISSN":["2044-5385"],"issn-type":[{"value":"2044-5385","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,12,14]]},"assertion":[{"value":"26 April 2017","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 September 2017","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 September 2017","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2017","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"B.L., O.A., and J.M.: none; S.K.: speaker Gilead. The remaining authors declare that they have no competing financial interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Publisher\u2019s note"}}],"article-number":"646"}}